Five patents currently held, every record listed here
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Sep 2036. from the record
Of the 2 now held by other companies, 2 name Research Foundation for the State University of New York as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Sep 2036
Next term end
4
Patent families
When these terms end
Each bar runs from grant to computed term end. 2020 to 2043.20252030203520402043
10 pending applications: term is not computable until grant.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Sep 2036 · High confidence
Also notable
Ends Apr 2038 · Low confidence
Bioorthogonal Compositions
US 10,828,373
The most cited patent in this portfolio, cited by 11 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2036.
Bioorthogonal Compositions
US 12,611,461
Granted 2026. Too new for citation comparison; protection runs to 2038. A terminal disclaimer caps this term to an earlier patent's.
Formerly held, still cited
Notable
Ends Aug 2038 · High confidence
Granted 2022. Computed term ends 2038.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Bioorthogonal Compositions (2018) | 2 in force | to Sep 2036 |
| Trans-Cyclooctene Prodrug of Monomethyl Auristatin E | 1 in force | to Mar 2043 |
| Processes for Preparing Functionalized Cyclooctenes | 1 in force | to Dec 2041 |
| Bioorthogonal Compositions (2025) | 1 in force | to Apr 2038 |
Patents held now
Soonest term end first.
Showing 1 to 5 of 5
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,828,373 | Bioorthogonal Compositions In force · High confidence | In force | High confidence | |
| US 12,527,874 | Bioorthogonal Compositions In force · High confidence | In force | High confidence | |
| US 12,611,461 | Bioorthogonal Compositions In force · Low confidence | In force | Low confidence | |
| US 12,194,100 | Processes for Preparing Functionalized Cyclooctenes In force · High confidence | In force | High confidence | |
| US 12,589,162 | Trans-Cyclooctene Prodrug of Monomethyl Auristatin E In force · High confidence | In force | High confidence |
Also on record, not counted in the 5: 2 patents in force now held by others · 10 applications pending · 2 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
2 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.